Letter by Rosenberg and Uretsky Regarding Article, “Risks Associated With Statin Therapy: A Systematic Overview of Randomized Clinical Trials”
To the Editor:
In regard to the article by Kashani et al,1 the authors conclude that “…statin therapy is associated with small excess risk of transminase elevations, but not of myalgias, creatine kinase elevations, rhabdomyolysis…”. We think this conclusion is misleading. On closer inspection of the data, atorvastatin has 3 times the occurrence of myalgias compared with placebo (P<0.04). According to the authors’ data, these adverse events seem to be unique to atorvastin and were not observed with other statins. Admittedly the absolute risk is small; however, when one considers that in the US alone ≈5 million patients are presently treated with atorvastatin, this drug could still account for myalgias in >250 000 patients—not quite an insignificant number!